|
Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Guillaume Abou Richard-Carpentier |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer |
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Nohla Therapeutics; Pfizer; Servier |
|
|
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Takeda |
Research Funding - Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst) |
|
|
Honoraria - Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb; Macrogenics; Orsenix; Pfizer; Seagen; Sunesis Pharmaceuticals; Xencor |
Consulting or Advisory Role - Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb; Macrogenics; Orsenix; Seagen; Sunesis Pharmaceuticals; Xencor |
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Macrogenics; Merck; Orsenix; Seagen; Sunesis Pharmaceuticals; Xencor |
|
|
Honoraria - Celgene; Incyte; LFB Biotechnologies; Novartis; Stemline Therapeutics |
Consulting or Advisory Role - Celgene; Incyte; LFB Biotechnologies; Novartis; Stemline Therapeutics |
Research Funding - Abbvie; Affymetrix/Thermo Fisher Scientific; Cellectis; Daiichi Sankyo; Incyte; Novartis; Plexxikon; Samus Therapeutics; Stemline Therapeutics |
Travel, Accommodations, Expenses - Celgene; mustangbio; Stemline Therapeutics |
|
|
Patents, Royalties, Other Intellectual Property - Acerta Pharma; Celgene; Genentech |
|
|
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Celgene; Helsinn Healthcare |
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Celgene; Jazz Pharmaceuticals |
Research Funding - Astex Pharmaceuticals; celgene |
|
|
Stock and Other Ownership Interests - Reata Pharmaceuticals |
Honoraria - Abbvie; Calithera Biosciences; Genentech |
Consulting or Advisory Role - AbbVie; Cellectis; Genentech/Roche; Stemline Therapeutics |
Research Funding - Abbvie (Inst); Ablynx (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Stemline Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Immunogen; Orsenix; Pfizer; Takeda |
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Agios; Bayer; Celgene; Karyopharm Therapeutics; MedImmune |
Consulting or Advisory Role - Agios; Celgene |
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo |